Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin

Enfortumab vedotin is a first-in-class Nectin-4-directed antibody-drug conjugate approved by the US Food and Drug Administration for the treatment of patients with locally advanced or metastatic urothelial cancer (la/mUC) previously treated with a platinum-based chemotherapy and a programmed death r...

Descripción completa

Detalles Bibliográficos
Autores principales: Lacouture, Mario E, Patel, Anisha B, Rosenberg, Jonathan E, O’Donnell, Peter H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Genitourinary Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914492/
https://www.ncbi.nlm.nih.gov/pubmed/35274723
http://dx.doi.org/10.1093/oncolo/oyac001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914492/
https://www.ncbi.nlm.nih.gov/pubmed/35274723
http://dx.doi.org/10.1093/oncolo/oyac001

Ejemplares similares